文档介绍：The Journal of the American Nutraceutical Association
Vol. 7, No. 1, Winter 2004 Reprint
R EVIEW A RTICLE
Homocysteine – A Risk Factor for Vascular
Diseases: Guidelines for the Clinical Practice
Thomas G. Guilliams, PhD
Director, Science and Regulatory Affairs,
Ortho Molecular Products Inc., Stevens Point, Wisconsin
Clinical Instructor, University of Wisconsin-Madison School of Pharmacy
A Peer-Reviewed Journal on Nutraceuticals and Nutrition
Editor-in-Chief
Mark Houston, .
ISSN-1521-4524
Reprinted with permission from the Journal of the American Nutraceutical Association.
Duplication in whole or part is not permitted without permission.
R EVIEW A RTICLE
Homocysteine – A Risk Factor for Vascular Diseases:
Guidelines for the Clinical Practice
Thomas G. Guilliams, PhD*
Director, Science and Regulatory Affairs,
Ortho Molecular Products Inc., Stevens Point, Wisconsin
Clinical Instructor, University of Wisconsin-Madison School of Pharmacy
ABSTRACT deficiencies, or itant ingestion of certain pharma-
As an emerging independent risk factor for cardiovas- ceuticals, homocysteine levels can rise beyond normal lev-
cular disease and other aging diseases such as Alzheimer’s, els and lead to adverse health es.
homocysteine-related research has generated a vast amount The role of elevated blood homocysteine levels in clin-
of literature and sparked a vigorous debate over the past ical practice is still being debated. The central question is,
decade. In fact, prehensive textbook is now available whether it is clinically beneficial to measure for and treat ele-
describing the role of homocysteine in health and vated levels of homocysteine?1,2 While some may consider
This review will survey the history of homocysteine homocysteine simply as a marker but not a treatable
research, the rationale for considering homocysteine as a causative agent, or perhaps ignore homocysteine as an
causative agent rather than just